LONDON - Trellus Health plc (AIM: TRLS), a provider of digital health solutions, has announced a partnership with Johnson & Johnson (NYSE:JNJ) Health Care Systems Inc. to pilot a program aimed at enhancing care for patients with inflammatory bowel disease (IBD) in the United States. The one-year pilot will integrate Trellus Health's platform, Trellus Elevate™, into patient support programs for those prescribed a Johnson & Johnson therapy.
Trellus Health will receive an undisclosed upfront licensing fee and a monthly management fee as part of the agreement. Trellus Elevate™ is designed to offer a holistic approach to patient care, combining data analytics with resilience-driven health programs. The collaboration seeks to address both the psychological and physiological aspects of IBD, which is a lifelong, incurable immune condition.
Dr. Marla Dubinsky, CEO of Trellus Health, emphasized the importance of addressing both mental and physical health to improve patient outcomes. "We have reached a therapeutic ceiling with many existing treatments for IBD," she said. The partnership aims to empower patients to manage their condition more effectively by providing comprehensive support.
This initiative marks Trellus Health's first significant venture into the pharmaceutical sector, following the identification of the sector as a strategic vertical in their September interim results. The company's approach is to provide an end-to-end solution that supports patients from clinical trials through to commercialization.
The collaboration with Johnson & Johnson is expected to help patients adhere to their treatment plans and improve their overall health journey by offering them the tools and support necessary to navigate the challenges of IBD. The information regarding this collaboration is now in the public domain, as stipulated by market regulation.
The announcement is based on a press release statement from Trellus Health plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.